Keith Pratz

Associate Professor

20052018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2018

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

Altman, J. K., Foran, J. M., Pratz, K. W., Trone, D., Cortes, J. E. & Tallman, M. S., Feb 1 2018, In : American Journal of Hematology. 93, 2, p. 213-221 9 p.

Research output: Contribution to journalArticle

Consolidation Chemotherapy
Induction Chemotherapy
Acute Myeloid Leukemia
Standard of Care
Drug Therapy

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., Chyla, B., Xu, T., Dunbar, M., Agarwal, S. K., Humerickhouse, R., Mabry, M., Potluri, J., Konopleva, M. & Pollyea, D. A., Feb 1 2018, In : The Lancet Oncology. 19, 2, p. 216-228 13 p.

Research output: Contribution to journalArticle

decitabine
Azacitidine
Acute Myeloid Leukemia
Safety
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship

on behalf of the ETCTN-6745 study team, Jul 1 2018, In : Clinical and Translational Science. 11, 4, p. 435-443 9 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 6
Metabolites

Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

O'Donnell, M. R. , Tallman, M. S. , Abboud, C. N. , Altman, J. K. , Appelbaum, F. R. , Arber, D. A. , Bhatt, V. , Bixby, D. , Blum, W. , Coutre, S. E. , De Lima, M. , Fathi, A. T. , Fiorella, M. , Foran, J. M. , Gore, S. D. , Hall, A. C. , Kropf, P. , Lancet, J. , Maness, L. J. , Marcucci, G. & 14 others Martin, M. G., Moore, J. O., Olin, R., Peker, D., Pollyea, D. A., Pratz, K., Ravandi, F., Shami, P. J., Stone, R. M., Strickland, S. A., Wang, E. S., Wieduwilt, M., Gregory, K. & Ogba, N., Jul 1 2017, In : JNCCN Journal of the National Comprehensive Cancer Network. 15, 7, p. 926-957 32 p.

Research output: Contribution to journalReview article

Practice Guidelines
Acute Myeloid Leukemia
Leukemia
Guidelines
Therapeutics

Acute myeloid leukemia in the elderly: therapeutic options and choice

Webster, J. A. & Pratz, K. W., Jun 2 2017, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-14 14 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Therapeutics
Comorbidity
Age Groups
Transplants